Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1492 • ACR Convergence 2021
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
Robert Clancy¹, Miranda Marion², Hannah Ainsworth², Miao Chang¹, Timothy Howard³, Peter Izmirly⁴, Mala Masson⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Wake Forest University, Quakertown, NC, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Wake Forest University, Winston Salem, NC
Background/Purpose: Unknown factors trigger the transition of anti-Ro+ mothers of neonatal lupus (NL) children from preclinical autoimmunity to clinical disease. One candidate may be the…
Abstract Number: 0073 • ACR Convergence 2021
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
Cecilia Chighizola¹, Francesca Pregnolato², Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Paul R Fortin⁸, Tatsuya Atsumi⁹, Maria Efthymiou,¹⁰, Guilherme Ramires de Jesus¹¹, D. Ware Branch¹², Cecilia Nalli¹³, Michelle Petri¹⁴, Esther Rodriguez-Almaraz¹⁵, Ricard Cervera¹⁶, Yu Zuo¹⁷, Rohan Willis¹⁸, Elisa Bison¹⁹, Ian Mackie²⁰, Hannah Cohen²¹, Robert Roubey²², Doruk Erkan²³ and Maria Laura Bertolaccini²⁴, ¹University of Milan, Milan, Italy, ²Università degli Studi di Milano, Milan, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸CHU de Quebec - Universite Laval, Québec City, QC, Canada, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Hospital Clinic Barcelona, Barcelona, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas Medical Branch, Galveston, TX, ¹⁹University of Padova, Padova, Italy, ²⁰University College London, London, United Kingdom, ²¹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ²²UNC, Chapel Hill, NC, ²³Hospital for Special Surgery, New York, NY, ²⁴King's College London, London, United Kingdom
Background/Purpose: Data on fluctuation of antibodies against domain 1 (anti-D1) of β2-glycoprotein I (β2GPI) are scarce. Patients with antiphospholipid syndrome (APS) and all three criteria…
Abstract Number: 0344 • ACR Convergence 2021
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Kuniyuki Aso¹, Michihito Kono¹, Keita Ninagawa¹, Nobuya Abe¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual¹, Kenji Oku¹ and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Sapporo, Japan
Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…
Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Jennifer Rogers¹, Rory Bloch², Amanda Eudy¹, David Pisetsky³, Roberta Alexander², John Conklin², Kai Sun¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²Exagen Inc., Vista, CA, ³Duke University Medical Center, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…
Abstract Number: 1501 • ACR Convergence 2021
Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS
Thomas McDonnell¹, Raj Amarnani², Valentina Spiteri², Carina Spicer³, Charis Pericleous⁴, Bahar Artim-Esen⁵, Ian Mackie¹, Marina Botto⁴, Anisur Rahman¹ and Ian Giles¹, ¹University College London, London, United Kingdom, ²University College London, London, ³Merck, Philadelphia, PA, ⁴Imperial College London, London, United Kingdom, ⁵Istanbul University School of Medicine, İstanbul, Turkey
Background/Purpose: The significance of antibodies directed against activated Factor (FXa) and thrombin (Thr) found in ~40% of patients with Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid…
Abstract Number: 0075 • ACR Convergence 2021
Endothelial Cell-activating Antibodies in COVID-19
Hui Shi¹, Yu Zuo², Sherwin Navaz², Alyssa Harbaugh², Claire Hoy², Alex Gandhi², Gautam Sule², Srilakshmi Yalavarthi², Kelsey Gockman², Jacqueline Madison², Jintao Wang², Melanie zuo², Yue Shi³, Michael Maile², Yogendra Kanthi² and Jason Knight², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Shanghai Sports School, Shanghai, China (People's Republic)
Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
Abstract Number: 0345 • ACR Convergence 2021
Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations
Eugene Krustev¹, Katherine Buhler¹, Francesca Cardwell², Marvin Fritzler¹, Ann Clarke¹ and May Choi³, ¹University of Calgary, Calgary, AB, Canada, ²University of Waterloo, Burlington, ON, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) can involve the central (CNS) and peripheral nervous system (PNS). Several autoantibodies have been associated with CNS NPSLE including…
Abstract Number: 0936 • ACR Convergence 2021
Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
Elif Ediboglu¹, Dilek Solmaz², Gokhan Kabadayi³, Mustafa Ozmen⁴, Kübra Kaya⁵, Muhammet Çınar⁶, Gökhan Sargın⁷, Gülen Hatemi⁸, Ömer Karadağ⁹, Gülay Kınıklı¹⁰, Onay Gercik¹¹, Umut Kalyoncu⁹, Sedat Yılmaz⁶, Taskın Şentürk⁷, Gokhan Keser¹², Figen Yargucu¹², Ayse Cefle¹³, Didem Kozacı⁵, Bünyamin Kısacık¹⁴ and Servet Akar², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Cigli Education and Research Hospital, İzmir, Turkey, ⁴katip çelebi university, izmir, Turkey, ⁵Yıldırım Beyazit University, Ankara, Turkey, ⁶Gülhane Education and Research Hospital, Ankara, Turkey, ⁷Adnan Menderes University, Aydın, Turkey, ⁸Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, İstanbul, Turkey, ⁹Hacettepe University, Ankara, Turkey, ¹⁰Ankara University, Ankara, Turkey, ¹¹Izmir Katip Celebi University, Izmir, Turkey, ¹²Ege University, İzmir, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Gaziantep Medicalpark Hospital, Gaziantep, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor…
Abstract Number: 1504 • ACR Convergence 2021
Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE
Erika Hubbard¹, David Pisetsky² and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Duke University Medical Center, Durham, NC
Background/Purpose: Anti-nuclear antibodies are important serologic features of SLE and facilitate diagnosis. Anti-double stranded DNA (dsDNA) antibodies are routinely monitored for disease prognosis and are…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 0962 • ACR Convergence 2021
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Arielle Mendel¹, Marvin Fritzler², Yvan St.Pierre¹, Joyce Rauch³, Sasha Bernatsky³ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although several studies indicate that patients with COVID-19 produce antiphospholipid antibodies (aPL), it is unclear which aPL subtype predominates and whether aPL correlates with…
Abstract Number: 1513 • ACR Convergence 2021
Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
Ryosuke Hiwa¹, Hailyn Nielsen¹, James Mueller¹ and Julie Zikherman², ¹University of California San Francisco, San Francisco, CA, ²UCSF Medical Center, San Francisco, CA
Background/Purpose: Current therapies for autoimmune disease often lead to treatment-limiting immunosuppression. Selective manipulation of antigen (Ag)-specific immune responses could enhance our therapeutic approach. Targeting members…
Abstract Number: 0195 • ACR Convergence 2020
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
Jennifer Hanberg¹, Kathleen Akgun², Liana Fraenkel³, Evelyn Hsieh² and Amy Justice⁴, ¹Yale University School of Medicine; West Haven VA, Boston, MA, ²Yale University School of Medicine; West Haven VA, New Haven, CT, ³Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ⁴Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
Abstract Number: 0773 • ACR Convergence 2020
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
Pauline Brevet¹, Manuel Freret¹, Pascal Rottenberg², Clément Guillou³, Thierry Lequerre⁴, Pascal Cosette⁵, Olivier Boyer² and Olivier Vittecoq⁶, ¹Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, ²Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, ³CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, ⁴Rheumatology, University Teaching Hospital, Rouen, France, ⁵CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, ⁶University Hospital of Rouen, Rouen, France
Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].